Tower Research Capital (TRC)’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $188 | Buy |
+127
| New | +$188 | ﹤0.01% | 5111 |
|
|
2024
Q4 | – | Sell |
-5,055
| Closed | -$5.16K | – | 5929 |
|
|
2024
Q3 | $5.16K | Sell |
5,055
-12,824
| -72% | -$13.1K | ﹤0.01% | 4318 |
|
|
2024
Q2 | $20.9K | Buy |
17,879
+13,986
| +359% | +$16.4K | ﹤0.01% | 3740 |
|
|
2024
Q1 | $4.91K | Sell |
3,893
-8,039
| -67% | -$10.1K | ﹤0.01% | 4615 |
|
|
2023
Q4 | $21.2K | Buy |
11,932
+5,179
| +77% | +$9.22K | ﹤0.01% | 3610 |
|
|
2023
Q3 | $11.2K | Buy |
6,753
+4,161
| +161% | +$6.91K | ﹤0.01% | 4022 |
|
|
2023
Q2 | $5.18K | Buy |
2,592
+990
| +62% | +$1.98K | ﹤0.01% | 4826 |
|
|
2023
Q1 | $3K | Buy |
+1,602
| New | +$3K | ﹤0.01% | 5225 |
|
|
2022
Q2 | – | Sell |
-6,465
| Closed | -$7K | – | 6428 |
|
|
2022
Q1 | $7K | Buy |
6,465
+6,393
| +8,879% | +$6.92K | ﹤0.01% | 4748 |
|
|
2021
Q4 | $0 | Buy |
+72
| New | – | ﹤0.01% | 6465 |
|
|
2021
Q3 | – | Sell |
-4,658
| Closed | -$9K | – | 6071 |
|
|
2021
Q2 | $9K | Buy |
4,658
+3,570
| +328% | +$6.9K | ﹤0.01% | 4444 |
|
|
2021
Q1 | $5K | Buy |
+1,088
| New | +$5K | ﹤0.01% | 4682 |
|
|
2015
Q2 | – | Sell |
-41
| Closed | -$1K | – | 4899 |
|
|
2015
Q1 | $1K | Sell |
41
-102
| -71% | -$2.49K | ﹤0.01% | 4108 |
|
|
2014
Q4 | $3K | Sell |
143
-103
| -42% | -$2.16K | ﹤0.01% | 3135 |
|
|
2014
Q3 | $6K | Sell |
246
-21
| -8% | -$512 | ﹤0.01% | 3178 |
|
|
2014
Q2 | $10K | Buy |
267
+6
| +2% | +$225 | ﹤0.01% | 2372 |
|
|
2014
Q1 | $12K | Buy |
261
+68
| +35% | +$3.13K | ﹤0.01% | 2433 |
|
|
2013
Q4 | $7K | Buy |
193
+35
| +22% | +$1.27K | ﹤0.01% | 3303 |
|
|
2013
Q3 | $7K | Buy |
158
+119
| +305% | +$5.27K | ﹤0.01% | 3452 |
|
|
2013
Q2 | $2K | Buy |
+39
| New | +$2K | ﹤0.01% | 3498 |
|